During the last session, Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s traded shares were 1.2 million, with the beta value of the company hitting 0.13. The 52-week high for the KPTI share is $4.11, that puts it down -277.06 from that peak though still a striking 43.12% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $126.95M, and the average trade volume was 1.79 million shares over the past three months.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
The stock’s 5-day price performance is -21.01%, and it has moved by -21.58% in 30 days. Based on these gigs, the overall price performance for the year is -73.35%.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
Statistics show that Karyopharm Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Karyopharm Therapeutics Inc (KPTI) shares have gone up 5.83% during the last six months, with a year-to-date growth rate less than the industry average at 4.80% against 10.20. In the rating firms’ projections, revenue will increase 0.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 34.47M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 36.42M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 36.6M and 37.58M respectively. In this case, analysts expect current quarter sales to shrink by -5.80% and then drop by -3.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 16.79%. While earnings are projected to return 1.62% in 2024.
KPTI Dividends
Karyopharm Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
